An invitation to update your knowledge about SPIRIVA® Respimat®
We invite you to visit the Boehringer Ingelheim exhibit booth at the ERS 2017 to hear real world experience with SPIRIVA® Respimat® for asthma treatment.
Dr Miguel Roman Rodriguez
Family Physician, IdisPa Balearic Health Research Institute, Palma de Mallorca, Spain
"We can see a lot of studies and we have enough data to say that patients can beneficiate from SPIRIVA® Respimat® in asthma, to reduce exacerbations"
Professor Leonard Fromer, MD, FAAFP
Family Physician, Executive Medical Director, Group Practice Forum, Los Angeles, USA
"The excitement around that new option is that we have an agent where we’ve shown, the world has seen, research shows efficacy and safety"
Some asthma patients want to be more physically active, but symptoms are preventing them from doing what they like.
SPIRIVA® Respimat® added on to at least ICS/LABA demonstrated* 68% more likely to improve asthma control1† and 21% risk reduction for first severe asthma exacerbation,2‡ with a safety profile comparable to placebo.
For your patients, consider adding SPIRIVA® Respimat®and help them stay ahead
Asthma add on-on treatment
For adult asthma patients who are currently treated with the maintentance combination of ICS (≥800 μg budesonide/day or equivalent) and LABA who experienced ≥1 severe exacerbations in the previous year.3
ICS=inhaled corticosteroid; LABA=long-acting b2 agonist
*Compared with placebo + at least ICS/LABA. † Control was assessed using ACQ-7. A patient was considered to be a responder if an improvement (decrease) in the ACQ total score of at least 0.5 points was reported. ‡ Severe asthma exacerbations were predefined in the clinical trial protocol as all asthma exacerbations that required treatment with systemic (including oral corticosteroids for at least 3 days, or, in the case of ongong and pre-existing systemic corticosteroid therapy, that required at least a doubling of the previous daily dose of systemic corticosteroids for at least 3 days.